Aptose Biosciences Inc. (NASDAQ:APTO) does about 843.97K shares in volume on a normal day but saw 3074219 shares change hands in Tuesday trading. The company now has a market cap of 496.92M USD and an enterprise value of about $359.03M. Its current market price is $6.15, marking an increase of 9.82% compared to the previous close of $5.60. The 52 week high reached by this stock is $9.25 whilst the lowest price level in 52 weeks is $1.82. The script in recent trading has seen the stock touch a high of $6.16 and a low of $5.37.

Aptose Biosciences Inc. (APTO) has a 20-day trading average at $5.17 and the current price is -33.53% off the 52-week high compared with 237.91% distance from its 52-week low. The 50-day simple moving average of the closing price is $5.53 and its 200-day simple moving average is $6.08. If we look at the stock’s price movements over the week, volatility stands at 7.27%, which decreases to 5.75% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 67.47 to suggest the stock is neutral.

7 analysts observing the Aptose Biosciences Inc. (APTO) stock have set the 12-month price targets for the company’s shares at between $9.00 and $13.00. The consensus objective for the share price is $4.72, suggesting that the stock has a potential downside of -30.3% over the period. The median price target is 38.5% away from the current levels at $10.00.

FactSet Research has provided data showing that 7 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 7 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on February 20, 2020 when Maxim Group initiated the stock to “Buy” and issued a price target of $16. Piper Sandler initiated its price target at $10.

The current price level is 20.06%, 10.91%, and 1.53% away from its SMA20, SMA50, and SMA200 respectively, with the APTO price moving below the 50-day SMA on September 01. Aptose Biosciences Inc. (APTO) stock is up 21.54% over the week and 18.27% over the past month. Its price is 8.47% year-to-date and 159.49% over the past year.

The stock last released its quarterly earnings report for quarter ended 9/29/2017, with the company’s earnings per share (EPS) of -$0.11 above consensus estimates by $0.04. The company’s next earnings report is expected on 11/17/2020, with forecasts estimating quarterly EPS at -$0.14 and -$0.86 for whole year. APTO’s earnings per share are forecast to grow by 25.20% this year and 37.20% over next year.

Its 12-month price target is $10.00. To reach the target analysts have set, the stock logically needs to shrink -30.3 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $9.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $13.00.

Outstanding shares total 76.28M with insiders holding 7.34% of the shares and institutional holders owning 40.63% of the company’s common stock. The company has a return on equity of -58.10%. The beta has a value of 1.64. Price to book ratio is 5.91.

According to a U.S. Securities and Exchange Commission filing, Polar Capital Funds Plc – Biotech has reduced its position in Aptose Biosciences Inc. (APTO) to 1,250,000 shares, mirroring a recent drop by 0.00%. Polar Capital Funds Plc – Biotech dumped 0.0 shares of Aptose Biosciences Inc. common stock bringing its total worth to about $6.33 million at the end of recent close, SEC documents show.